This personalized antibody–antigen-complex-based cancer vaccine, with KLH as the carrier protein as well as conjugated to adjuvant CpG ODN and neoantigen peptides, not only has strong immunogenicity but also improves the utilization rate of neoantigen peptides in the body, significantly activating CD8+ T cells and enhancing the antitumor immune response. Here, CD8A is linked to cancer.